Online Course: Quo vadis, SPC?

Detailed programme Cours: 1st day: 13:00 - 17:15 CET | 2nd day: 13:00 - 17:15 CET | 3nd day: 09:00 - 13:15 CET Pre-Course: Introduction to the basic terms

Structure of the EU SPC Regulation for Medicinal Products

Product - relevant deadlines - basic patent - relevant marketing authorisation

Pre-Course: Fundamental practical questions

What can be protected?

Application for a certificate based on third parties' authorisation

Date of grant of the basic patent and the marketing authorisation

Advanced Course: From Merck vs Sigma to Santen

Merck v Sigma (C-579/13), Pfizer Ireland (C-681/16): referrals on Specific Mechanism

Synflorix (C-631/13): definition of adjuvant

Boehringer (C-577/13): combination claimed in second patent

Forsgren (C-631/13): covalent binding of a biologic product

Seattle Genetics (C-471/14): date of market authorisation

F. Hoffmann - La Roche (C-572/15): duration of an SPC issued under national law

Incyte (C-492/16): date of expiry of an SPC

MSD (C-567/16): end of procedure notice equivalent to market authorisation?

Teva v Gilead (C-121/17): product protected by a basic patent in force

Boston Scientific (C-527/17): no SPCs for CE-marked devices

Abraxis (C-443/17): first marketing authorisation for new formulations

QH/Royalty Pharma (C 650/17): individualized embodiment

Santen v INPI (C-673/18): no SPC for new therapeutic applications

Advanced Course: Open questions for further potential referrals

Detailed programme Cours: 1st day: 13:00 - 17:15 CET | 2nd day: 13:00 - 17:15 CET | 3nd day: 09:00 - 13:15 CET Pre-Course: Introduction to the basic terms

Structure of the EU SPC Regulation for Medicinal Products

Product - relevant deadlines - basic patent - relevant marketing authorisation

Pre-Course: Fundamental practical questions

What can be protected?

Application for a certificate based on third parties' authorisation

Date of grant of the basic patent and the marketing authorisation

Advanced Course: From Merck vs Sigma to Santen

Merck v Sigma (C-579/13), Pfizer Ireland (C-681/16): referrals on Specific Mechanism

Synflorix (C-631/13): definition of adjuvant

Boehringer (C-577/13): combination claimed in second patent

Forsgren (C-631/13): covalent binding of a biologic product

Seattle Genetics (C-471/14): date of market authorisation

F. Hoffmann - La Roche (C-572/15): duration of an SPC issued under national law

Incyte (C-492/16): date of expiry of an SPC

MSD (C-567/16): end of procedure notice equivalent to market authorisation?

Teva v Gilead (C-121/17): product protected by a basic patent in force

Boston Scientific (C-527/17): no SPCs for CE-marked devices

Abraxis (C-443/17): first marketing authorisation for new formulations

QH/Royalty Pharma (C 650/17): individualized embodiment

Santen v INPI (C-673/18): no SPC for new therapeutic applications

Advanced Course: Open questions for further potential referrals

Detailed programme
Detailed programme
Cours: 1st day: 13:00 - 17:15 CET | 2nd day: 13:00 - 17:15 CET | 3nd day: 09:00 - 13:15 CET
Cours: 1st day: 13:00 - 17:15 CET | 2nd day: 13:00 - 17:15 CET | 3nd day: 09:00 - 13:15 CET
Pre-Course: Introduction to the basic terms

Structure of the EU SPC Regulation for Medicinal Products

Product - relevant deadlines - basic patent - relevant marketing authorisation

Pre-Course: Fundamental practical questions

What can be protected?

Application for a certificate based on third parties' authorisation

Date of grant of the basic patent and the marketing authorisation

Advanced Course: From Merck vs Sigma to Santen

Merck v Sigma (C-579/13), Pfizer Ireland (C-681/16): referrals on Specific Mechanism

Synflorix (C-631/13): definition of adjuvant

Boehringer (C-577/13): combination claimed in second patent

Forsgren (C-631/13): covalent binding of a biologic product

Seattle Genetics (C-471/14): date of market authorisation

F. Hoffmann - La Roche (C-572/15): duration of an SPC issued under national law

Incyte (C-492/16): date of expiry of an SPC

MSD (C-567/16): end of procedure notice equivalent to market authorisation?

Teva v Gilead (C-121/17): product protected by a basic patent in force

Boston Scientific (C-527/17): no SPCs for CE-marked devices

Abraxis (C-443/17): first marketing authorisation for new formulations

QH/Royalty Pharma (C 650/17): individualized embodiment

Santen v INPI (C-673/18): no SPC for new therapeutic applications

Advanced Course: Open questions for further potential referrals

Pre-Course: Introduction to the basic terms

Structure of the EU SPC Regulation for Medicinal Products

Product - relevant deadlines - basic patent - relevant marketing authorisation

Pre-Course: Fundamental practical questions

What can be protected?

Application for a certificate based on third parties' authorisation

Date of grant of the basic patent and the marketing authorisation

Advanced Course: From Merck vs Sigma to Santen

Merck v Sigma (C-579/13), Pfizer Ireland (C-681/16): referrals on Specific Mechanism

Synflorix (C-631/13): definition of adjuvant

Boehringer (C-577/13): combination claimed in second patent

Forsgren (C-631/13): covalent binding of a biologic product